The case for Teledyne Technologies paying $18.90 a share for Varex Imaging rests on portfolio logic that the companies have been building toward separately for years. The complication: the all-cash deal, valued at roughly $1.1 billion including Varex's equity awards and net debt as of 3 April 2026, still requires regulatory approvals and a Varex stockholder vote, with closing targeted for no earlier than early 2027.

What Varex brings and what Teledyne is paying for

Varex supplies X-ray sources and imaging software to original equipment manufacturers in medical diagnostic imaging and industrial markets, with a global workforce of around 2,400 employees across Asia, Europe, and North America. Teledyne will pay $18.90 per share for all outstanding Varex common shares, a price both boards approved unanimously. Varex chief executive Sunny Sanyal called the premium substantial for shareholders and said the company's X-ray technologies sit naturally alongside Teledyne's existing product lines.

Teledyne executive chairman Robert Mehrabian reached back to a precedent: the 2017 acquisition of Teledyne e2v, a long-term magnetron supplier to cancer radiotherapy OEMs. That deal's logic echoes here. Teledyne has a demonstrated template for absorbing niche scientific hardware businesses that serve specialized OEM customers, then using the parent's scale to push the product roadmap further. Sanyal said Teledyne's backing should accelerate adoption of Varex's advanced imaging solutions and help develop the next generation of products.

The counterargument

The read-through that argues against a smooth close is regulatory. Medical imaging supply chains draw scrutiny from antitrust reviewers, and early 2027 is a target, not a commitment. Evercore is advising Varex on the financial side, with Orrick, Herrington & Sutcliffe as legal counsel; Teledyne has retained Latham & Watkins and McGuireWoods. Advisory rosters this deep suggest both sides are preparing for a process rather than a formality. Mehrabian's framing that the businesses carry "minimal overlap" is precisely the claim regulators will probe.

On balance

The strategic case is coherent: two OEM-facing businesses with adjacent technologies and limited product collision. On balance, the deal's durability depends on that minimal-overlap claim surviving regulatory review. The agreed price is pegged to Varex's financial position as of 3 April 2026. The next figure that matters is whether stockholders and regulators agree before early 2027.

Related reading